# Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 Clinical Trial Optional)

Source: https://welltoldgrants.com/grants/rfa-hl-21-014-understanding-and-reducing-cardiovascular-disease-in-type-1/  
Official notice: https://www.grants.gov/search-results-detail/330742

> National Institutes of Health offered grants of up to $500,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make about 8 awards worth $6.2 million in total. Applications closed on October 15, 2021.

| Field | Value |
|---|---|
| Opportunity number | RFA-HL-21-014 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | October 15, 2021 |
| Award ceiling | $500,000 |
| Award floor | not stated |
| Expected awards | 8 |
| Total funding | $6.2 million |
| Cost sharing | not required |
| Assistance Listings | 93.837, 93.847 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

## What the grant funds

The goal of this funding opportunity is to support research that enhances the understanding of the pathophysiology and epidemiology of cardiovascular disease (CVD) among individuals with Type 1 Diabetes Mellitus (T1DM), and support the development of interventions to reduce CVD risk among these individuals. The overall goal is to develop evidence-based guidelines to prevent or reduce CVD complications of T1DM across the lifespan. This funding opportunity will support epidemiologic studies to refine risk assessment, mechanistic studies to enhance understanding of the pathophysiology of CVD in T1DM, and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD complications of T1DM. The focus of this FOA is on macrovascular disease that includes outcomes of myocardial infarction, stroke, peripheral artery disease, heart failure, cardiomyopathy, cardiac arrythmias and cardiac autonomic neuropathy and/or the study of coronary arteries, cerebral arteries, large peripheral arteries, cardiac tissue, atherosclerosis, thrombosis and lipoprotein metabolism. Research can include the effect of microvascular disease on the development of macrovascular disease, e.g., DKD, but the emphasis must be on CVD.

## Questions people ask

### Is RFA-HL-21-014 still open?

No. It closed on October 15, 2021.

### Who can apply for Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 Clinical Trial Optional)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 Clinical Trial Optional)?

Closed October 15, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $500,000 each. About $6.2 million in total across about 8 awards.

### Who has been funded under RFA-HL-21-014?

NIH RePORTER lists 7 projects funded under RFA-HL-21-014 in fiscal 2022 to 2026, at 6 institutions. The most were at Joslin Diabetes Center, Mayo Clinic Rochester, New York University School of Medicine.

### Who has won Cardiovascular Diseases Research grants before?

The largest recipients over five fiscal years were The Trustees of the University of Pennsylvania, Brigham & Womens Hospital Inc, Regents of the University of Michigan. The program made 11,798 awards worth $15 billion in that time.